SGLT-2 Inhibitors for Reduction of Hypoglycaemia After Bariatric Surgery

The European Patent Office published patent application EP3908274A1 by Universitätsspital Basel for the use of SGLT-2 inhibitors to reduce hypoglycaemia in patients who have undergone bariatric surgery. The application covers pharmaceutical compositions containing SGLT-2 inhibitors for this specific medical indication. The patent is designated across 34 European states including major markets.

Human CD3 Binding Antibody Patent

The European Patent Office published patent application EP3757129A1 for Merus B.V., covering a human CD3 binding antibody. The application, filed by inventors Bakker and van Loo, claims priority dates back to October 2020 and designates 31 European states. This publication makes the patent claims publicly available, establishing priority dates and technical scope for the CD3-targeted antibody therapeutic.

Coenzyme Q10 Brain Cancer Treatment Patent

The European Patent Office published patent application EP3730131A1 for BPGbio Inc., covering a method of treating brain cancer through continuous infusion of Coenzyme Q10. The patent lists nine inventors and multiple IPC classifications related to pharmaceutical compositions. The application designates all EU contracting states and several additional European countries.

Inhalable Cyclodextrin Composition for Nasal Inflammation Treatment

The European Patent Office published patent application EP3993810A1 for Aquilon Pharmaceuticals, covering an inhalable cyclodextrin composition for treating nasal inflammations. The patent names inventors Cataldo Didier, Albert Marie-Astrid, and Maes Paul. The application designates 35 European contracting states.

Alkermes subcutaneous cancer immunotherapy compositions patent

European Patent Office published patent application EP3982998A1 for Alkermes Pharma Ireland Limited covering compositions and methods for subcutaneous administration of cancer immunotherapy. The patent lists inventors Heather C. Losey, Jared Lopes, Lei Sun, and Raymond J. Winquist. Designated states include all European Patent Convention member states.

Polymer-lipid Nanocomplex for Enhanced Hydrophobic Drug Solubility

The European Patent Office published patent application EP3941439A1 for the Council for Scientific and Industrial Research covering a polymer-lipid nanocomplex formulation that enhances aqueous solubilisation and absorption of hydrophobic active compounds. The invention addresses drug delivery challenges for poorly soluble pharmaceuticals across multiple therapeutic areas including anti-obesity, anxiolytic, antidepressant, anti-inflammatory, antimicrobial, and antiparasitic applications.

Nestlé dietary butyrate patent for therapeutic compositions

The European Patent Office published Nestlé patent application EP3972422A1 for dietary butyrate compositions with therapeutic applications. Société des Produits Nestlé S.A. seeks protection for butyrate-based compositions for treating digestive and metabolic disorders. The patent names inventors Patin, Forbes-Blom, and Kulkarni, with designated states covering major European markets including Germany, France, UK, Italy, and Spain.

APRA Grants General Insurance Licence to Europ Assistance Australia

APRA granted Europ Assistance Australia Pty Ltd a licence to operate as a general insurer under the Insurance Act 1973. The licence authorises the company to conduct general insurance business in Australia. APRA maintains a public register of all authorised general insurers.

Consumer Warning: Unauthorized Crypto Scheme calculusinv.com CVUZ Token

BaFin issued a consumer warning on 2026-04-01 regarding Calculus Investments Ltd, which claims to operate from New York and Frankfurt but provides unauthorized financial, investment, and cryptoasset services through calculusinv.com and the GVEXPRO app. The regulator suspects the presented founder, Prof. Tobias Fischer, does not exist, and consumers purchasing CVUZ tokens via this scheme are likely to lose their invested funds.

BaFin warns against unauthorized crypto offerings by Calculus Investments Ltd

BaFin issued a consumer protection warning against Calculus Investments Ltd for offering cryptocurrency and financial services without required authorization. The entity operates through the website calculusinv.com and social media channels, promoting the CVUZ-TOKEN via the GVEXPRO trading app. Deposited funds are considered highly likely to be lost, and BaFin identifies the purported founder Prof. Tobias Fischer as likely fictitious.